Active, not recruitingPhase 2NCT04657094
Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia
Studying Autoimmune hemolytic anemia, warm type
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- City of Hope Medical Center
- Principal Investigator
- Alexey Danilov, M.DCity of Hope Medical Center
- Intervention
- Acalabrutinib(drug)
- Enrollment
- 4 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2026
Study locations (1)
- City of Hope Medical Center, Duarte, California, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04657094 on ClinicalTrials.govOther trials for Autoimmune hemolytic anemia, warm type
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07039422Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From IanalumabNovartis Pharmaceuticals
- RECRUITINGEARLY PHASE1NCT07530380UCAR T-cell Therapy Targeting CD19/BCMA in Relapsed/Refractory Autoimmune Hemolytic AnemiaThe Second Hospital of Anhui Medical University
- RECRUITINGNANCT05925023Sirolimus in the Treatment of Refractory/Relapsed wAIHAPeking Union Medical College Hospital
- ACTIVE NOT RECRUITINGPHASE3NCT05648968A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic AnemiaNovartis Pharmaceuticals
- ACTIVE NOT RECRUITINGPHASE2NCT05002777Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)Sanofi